bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S3 from Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma
Authors: Jain Salvia , Washington Abigail , Leaf Rebecca Karp , Bhargava Parul , Clark Rachael A. , Kupper Thomas S. , Stroopinsky Dina , Pyzer Athalia , Cole Leandra , Nahas Myrna , Apel Arie , Rosenblatt Jacalyn , Arnason Jon , Kufe Donald , Avigan David
Published: April 2023

A schema of the various CpG locations that were analyzed in the Nox4 promoter of the gene is presented
Supplementary Methods from An In Vivo Functional Screen Identifies JNK Signaling As a Modulator of Chemotherapeutic Response in Breast Cancer
Authors: Ashenden Matthew , van Weverwijk Antoinette , Murugaesu Nirupa , Fearns Antony , Campbell James , Gao Qiong , Iravani Marjan , Isacke Clare M.
Published: April 2023

Supplementary Methods
Supplementary Figures S1-S7 from Ovarian Primary and Metastatic Tumors Suppressed by Survivin Knockout or a Novel Survivin Inhibitor
Authors: Zhao Guannan , Wang Qinghui , Wu Zhongzhi , Tian Xinchun , Yan Huan , Wang Baojin , Dong Peixin , Watari Hidemichi , Pfeffer Lawrence M. , Guo Yuqi , Li Wei , Yue Junming
Published: April 2023

Supplementary Figure S1. Survivin and EMT markers were stained in sections of ovarian tumor of survivin KO and control mice; Supplementary Figure S2. Ovarian cancer cell migration and invasion following inhibition of apoptosis; Supplementary Figure S3. Cell viability in the upper chamber following treatment of MX106 in the migration assay; Supplementary Figure S4. Cell viability in the upper chamber following treatment of MX106 in the invasion assay; Supplementary Figure S5. SMAD dependent reporter gene luciferase activity; Supplementary Figure S6. TGFβ did not activate non-SMAD pathway in ovarian cancer cells; Supplementary Figure S7. Immunostaining for survivin and EMT markers in sections of ovarian tumor tissue following MX106 or vehicle treatment.
Supplementary Table S2 from Selective Inhibition of ADAM28 Suppresses Lung Carcinoma Cell Growth and Metastasis
Authors: Mochizuki Satsuki , Shimoda Masayuki , Abe Hitoshi , Miyamae Yuka , Kuramoto Junko , Aramaki-Hattori Noriko , Ishii Ken , Ueno Hideki , Miyakoshi Akira , Kojoh Kanehisa , Okada Yasunori
Published: April 2023

Supplementary Table S2 shows hematological and biochemical results of mice treated with control mouse IgG or antibody 211-12 at 20 mg/kg body weight five times once a week.
Supplementary Table S1 from Selective Inhibition of ADAM28 Suppresses Lung Carcinoma Cell Growth and Metastasis
Authors: Mochizuki Satsuki , Shimoda Masayuki , Abe Hitoshi , Miyamae Yuka , Kuramoto Junko , Aramaki-Hattori Noriko , Ishii Ken , Ueno Hideki , Miyakoshi Akira , Kojoh Kanehisa , Okada Yasunori
Published: April 2023

Supplementary Table S1 shows information about primers used for RT-PCR.
Supplementary Figure Legends from CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory
Authors: Benonisson Hreinn , Altıntaş Işıl , Sluijter Marjolein , Verploegen Sandra , Labrijn Aran F. , Schuurhuis Danita H. , Houtkamp Mischa A. , Verbeek J. Sjef , Schuurman Janine , van Hall Thorbald
Published: April 2023

legends
Figure S3 from A Short SOX9 Peptide Mimics SOX9 Tumor Suppressor Activity and Is Sufficient to Inhibit Colon Cancer Cell Growth
Authors: Blache Philippe , Canterel-Thouennon Lucile , Busson Muriel , Verdié Pascal , Subra Gilles , Ychou Marc , Prévostel Corinne
Published: April 2023

Crystal violet staining (n = 6) at day 11 post-seeding demonstrates that mutation of the conserved aspartic acid residue into alanine in the S9pep N-terminus only slightly reduces S9pep effect on DLD-1 cell growth compared with wild type S9pep. By contrast, SOX9K205-G225 abolishes the S9pep effect on DLD-1 cell growth.
Figure S2 from A Short SOX9 Peptide Mimics SOX9 Tumor Suppressor Activity and Is Sufficient to Inhibit Colon Cancer Cell Growth
Authors: Blache Philippe , Canterel-Thouennon Lucile , Busson Muriel , Verdié Pascal , Subra Gilles , Ychou Marc , Prévostel Corinne
Published: April 2023

SOX-luciferase reporter assay (n = 3) shows SOX activity in DLD-1 cells after induction or not of SOX9 (S9-DLD-1 cells, used here as a positive control) or S9pep (S9pep-DLD-1 cells) by incubation with doxycycline. While SOX activity is, as expected, drastically increased in response to doxycycline-induced SOX9 expression, doxycycline-induced S9pep expression has no significant effect.
Figure S1 from A Short SOX9 Peptide Mimics SOX9 Tumor Suppressor Activity and Is Sufficient to Inhibit Colon Cancer Cell Growth
Authors: Blache Philippe , Canterel-Thouennon Lucile , Busson Muriel , Verdié Pascal , Subra Gilles , Ychou Marc , Prévostel Corinne
Published: April 2023

Figure S1. Western blot analysis of PKCα expression showing that none of the doxyxcycline-induced expression of flagged 2NLS-SOX9(short sequences within 208-303) such as 2NLS-SOX9(208-247) or 2NLS-SOX9 (208-229) enhanced PKCα expression in genetically modified DLD-1 cells exposed to 1μg/ml doxycycline for 24, 48 and up to 72hours (50μg of total protein extracts were run per lane, loading control is β-actin).
Figure S6 from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
Authors: Zhao Genshi , Green Colin F. , Hui Yu-Hua , Prieto Lourdes , Shepard Robert , Dong Sucai , Wang Tao , Tan Bo , Gong Xueqian , Kays Lisa , Johnson Robert L. , Wu Wenjuan , Bhattachar Shobha , Del Prado Miriam , Gillig James R. , Fernandez Maria-Carmen , Roth Ken D. , Buchanan Sean , Kuo Ming-Shang , Geeganage Sandaruwan , Burkholder Timothy P.
Published: April 2023

Association of NAPRT1 expression level with sensitivity of cancer cells to NAMPT inhibition by LSN3154567 in the presence of NA
Figure S4 from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
Authors: Zhao Genshi , Green Colin F. , Hui Yu-Hua , Prieto Lourdes , Shepard Robert , Dong Sucai , Wang Tao , Tan Bo , Gong Xueqian , Kays Lisa , Johnson Robert L. , Wu Wenjuan , Bhattachar Shobha , Del Prado Miriam , Gillig James R. , Fernandez Maria-Carmen , Roth Ken D. , Buchanan Sean , Kuo Ming-Shang , Geeganage Sandaruwan , Burkholder Timothy P.
Published: April 2023

A and B, NCI-H1155 and HCT116 cells were grown and treated in duplicates with LSN3154567 (100 nM), respectively, as described (Materials and Methods) and apoptosis was analyzed as described above.
Supplementary Tables S1-S9 from Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type
Authors: Wang Yemin , Chen Shary Yuting , Colborne Shane , Lambert Galen , Shin Chae Young , Santos Nancy Dos , Orlando Krystal A. , Lang Jessica D. , Hendricks William P.D. , Bally Marcel B. , Karnezis Anthony N. , Hass Ralf , Underhill T. Michael , Morin Gregg B. , Trent Jeffrey M. , Weissman Bernard E. , Huntsman David G.
Published: April 2023

Table S1 shows the cell viability inhibitory rate (%) in SCCOHT cell lines vs other cell lines in the epigenetic drug screen. Table S2 shows the effects of Quisinostat on the proteome of BIN67 cells after treatment for 24 or 72 hours. Table S3 shows the significantly altered proteins by Quisinostat treatment for 24 hours in BIN67 cells. Table S4 shows the significantly altered proteins by Quisinostat treatment for 72 hours in BIN67 cells. Table S5 shows the biological functions that were significantly affected by Quisinostat treatment for 72 hours in BIN67 cells. Table S6 shows the proteins that were significantly regulated by SMARCA4 re-expression in BIN67 cells. Table S7 shows the biological functions that were significantly affected by SMARCA4 re-expression in BIN67 cells. Table S8 shows the proteins that were significantly regulated by both Quisinostat treatment (72 hr) and SMARCA4 re-expression in BIN67 cells. Table S9 shows the biological functions that were significantly affected by both Quisinostat and SMARCA4 re-expression in BIN67 cells.
Supplementary Figure S3 from Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer
Authors: O'Brien Neil , Conklin Dylan , Beckmann Richard , Luo Tong , Chau Kevin , Thomas Josh , Mc Nulty Ann , Marchal Christophe , Kalous Ondrej , von Euw Erika , Hurvitz Sara , Mockbee Colleen , Slamon Dennis J.
Published: April 2023

Keratin-19 Protein Levels are not Regulated by Abemaciclib
Supplementary Figures from Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas
Authors: Chang Long-Sheng , Oblinger Janet L. , Burns Sarah S. , Huang Jie , Anderson Larry W. , Hollingshead Melinda G. , Shen Rulong , Pan Li , Agarwal Garima , Ren Yulin , Roberts Ryan D. , O'Keefe Barry R. , Kinghorn A. Douglas , Collins Jerry M.
Published: April 2023

Supplementary Figures S1-S7
Supplementary Table S1 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Authors: Shibata Tomohiro , Watari Kosuke , Kawahara Akihiko , Sudo Tomoya , Hattori Satoshi , Murakami Yuichi , Izumi Hiroto , Itou Junji , Toi Masakazu , Akiba Jun , Akagi Yoshito , Tanaka Maki , Kuwano Michihiko , Ono Mayumi
Published: April 2023

Overview of pathological diagnosis and treatment status of patients refractory to endocrine therapeutics.
Figure S6 from Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer
Authors: Kawai Yoshihisa , Imada Kenjiro , Akamatsu Shusuke , Zhang Fan , Seiler Roland , Hayashi Tetsutaro , Leong Jeffrey , Beraldi Eliana , Saxena Neetu , Kretschmer Alexander , Oo Htoo Zarni , Contreras-Sanz Alberto , Matsuyama Hideyasu , Lin Dong , Fazli Ladan , Collins Colin C. , Wyatt Alexander W. , Black Peter C. , Gleave Martin E.
Published: April 2023

PEG10 knockdown attenuates in vivo tumor growth.
Figure S3 from Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer
Authors: Kawai Yoshihisa , Imada Kenjiro , Akamatsu Shusuke , Zhang Fan , Seiler Roland , Hayashi Tetsutaro , Leong Jeffrey , Beraldi Eliana , Saxena Neetu , Kretschmer Alexander , Oo Htoo Zarni , Contreras-Sanz Alberto , Matsuyama Hideyasu , Lin Dong , Fazli Ladan , Collins Colin C. , Wyatt Alexander W. , Black Peter C. , Gleave Martin E.
Published: April 2023

PEG10 triggers phosphorylation of Rb protein and promotes the proliferation of bladder cancer cells.
Supplementary Materials and Methods from Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
Authors: Kotanides Helen , Sattler Rose Marie , Lebron Maria B. , Carpenito Carmine , Shen Juqun , Li Jingxing , Surguladze David , Haidar Jaafar N. , Burns Colleen , Shen Leyi , Inigo Ivan , Pennello Anthony L. , Forest Amelie , Chen Xinlei , Chin Darin , Sonyi Andreas , Topper Michael , Boucher Lauren , Sharma Prachi , Zhang Yiwei , Burtrum Douglas , Novosiadly Ruslan D. , Ludwig Dale L. , Plowman Gregory D. , Kalos Michael
Published: April 2023

Supplementary Materials and Methods
Figure S8 from Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
Authors: Kotanides Helen , Sattler Rose Marie , Lebron Maria B. , Carpenito Carmine , Shen Juqun , Li Jingxing , Surguladze David , Haidar Jaafar N. , Burns Colleen , Shen Leyi , Inigo Ivan , Pennello Anthony L. , Forest Amelie , Chen Xinlei , Chin Darin , Sonyi Andreas , Topper Michael , Boucher Lauren , Sharma Prachi , Zhang Yiwei , Burtrum Douglas , Novosiadly Ruslan D. , Ludwig Dale L. , Plowman Gregory D. , Kalos Michael
Published: April 2023

Figure S8 shows tumor volume graph of NCI-H292 human tumor xenograft
Supplementary Figure 3 from High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers
Authors: Riviere Paul , Goodman Aaron M. , Okamura Ryosuke , Barkauskas Donald A. , Whitchurch Theresa J. , Lee Suzanna , Khalid Noor , Collier Rachel , Mareboina Manvita , Frampton Garrett M. , Fabrizio David , Sharabi Andrew B. , Kato Shumei , Kurzrock Razelle
Published: April 2023

Supplementary Figure 3
Figure S3 from Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
Authors: Kotanides Helen , Sattler Rose Marie , Lebron Maria B. , Carpenito Carmine , Shen Juqun , Li Jingxing , Surguladze David , Haidar Jaafar N. , Burns Colleen , Shen Leyi , Inigo Ivan , Pennello Anthony L. , Forest Amelie , Chen Xinlei , Chin Darin , Sonyi Andreas , Topper Michael , Boucher Lauren , Sharma Prachi , Zhang Yiwei , Burtrum Douglas , Novosiadly Ruslan D. , Ludwig Dale L. , Plowman Gregory D. , Kalos Michael
Published: April 2023

Figure S3 shows CD137 receptor modulation
Supplementary Figure 2 from High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers
Authors: Riviere Paul , Goodman Aaron M. , Okamura Ryosuke , Barkauskas Donald A. , Whitchurch Theresa J. , Lee Suzanna , Khalid Noor , Collier Rachel , Mareboina Manvita , Frampton Garrett M. , Fabrizio David , Sharabi Andrew B. , Kato Shumei , Kurzrock Razelle
Published: April 2023

Supplementary Figure 2
Figure S2 from Inhibition of EZH2 Enhances the Antitumor Efficacy of Metformin in Prostate Cancer
Authors: Kong Yifan , Zhang Yanquan , Mao Fengyi , Zhang Zhuangzhuang , Li Zhiguo , Wang Ruixin , Liu Jinghui , Liu Xiaoqi
Published: April 2023

AR expressions in various cell lines & combinational effects on PC3 and DU145
Figure S1 from Inhibition of EZH2 Enhances the Antitumor Efficacy of Metformin in Prostate Cancer
Authors: Kong Yifan , Zhang Yanquan , Mao Fengyi , Zhang Zhuangzhuang , Li Zhiguo , Wang Ruixin , Liu Jinghui , Liu Xiaoqi
Published: April 2023

Apoptosis of LNCaP and 22Rv1 in response to the treatments
Figure S4 from Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding
Authors: Puro Robyn J. , Bouchlaka Myriam N. , Hiebsch Ronald R. , Capoccia Benjamin J. , Donio Michael J. , Manning Pamela T. , Frazier William A. , Karr Robert W. , Pereira Daniel S.
Published: April 2023

Figure S4 demonstrates the minimal reduction in RBC and hemoglobin levels in cynomolgus monkeys treated with AO-176
Figure S2 from Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity
Authors: Zheng Zeliang , Okada Ryuhei , Kobayashi Hisataka , Nagaya Tadanobu , Wei Junxia , Zhou Qi , Lee Fred , Bera Tapan K. , Gao Yun , Kuhlman William , Tai Chin-Hsien , Pastan Ira
Published: April 2023

Mesothelin binding of PEGylated RITs
Table S1 from Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases
Authors: Koivu Marika K.A. , Chakroborty Deepankar , Tamirat Mahlet Z. , Johnson Mark S. , Kurppa Kari J. , Elenius Klaus
Published: April 2023

Table S1 shows cell line nomenclature.
Figure S1-S9 from Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases
Authors: Koivu Marika K.A. , Chakroborty Deepankar , Tamirat Mahlet Z. , Johnson Mark S. , Kurppa Kari J. , Elenius Klaus
Published: April 2023

Figures S1-S9 shows drug sensitivity and ERBB variant data for Figure S1-S9.
Supplementary Data from Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors
Authors: Kwan Amy , Winder Natalie , Atkinson Emer , Al-Janabi Haider , Allen Richard J. , Hughes Russell , Moamin Mohammed , Louie Rikah , Evans Dhanajay , Hutchinson Matthew , Capper Drew , Cox Katie , Handley Joshua , Wilshaw Adam , Kim Taewoo , Tazzyman Simon J. , Srivastava Sanjay , Ottewell Penelope , Vadakekolathu Jayakumar , Pockley Graham , Lewis Claire E. , Brown Janet E. , Danson Sarah J. , Conner Joe , Muthana Munitta
Published: April 2023

Supplementary Tables and Figures
Figure S2 from Design of a Cytotoxic Neuroblastoma-Targeting Agent Using an Enzyme Acting on Polysialic Acid Fused to a Toxin
Authors: Lehti Timo A. , Pajunen Maria I. , Jokilammi Anne , Korja Miikka , Lilie Hauke , Vettenranta Kim , Finne Jukka
Published: April 2023

Figure S2 shows a qualitative analysis of protein conjugates by SDS-PAGE.
Supplementary Video S2 from Development of a MUC16-Targeted Near-Infrared Fluorescent Antibody Conjugate for Intraoperative Imaging of Pancreatic Cancer
Authors: Olson Madeline T. , Wojtynek Nicholas E. , Talmon Geoffrey A. , Caffrey Thomas C. , Radhakrishnan Prakash , Ly Quan P. , Hollingsworth Michael A. , Mohs Aaron M.
Published: April 2023

Supplementary Video S2 shows surgical resection with IgG-IRDye800.
Supplementary Figure S3 from Development of a MUC16-Targeted Near-Infrared Fluorescent Antibody Conjugate for Intraoperative Imaging of Pancreatic Cancer
Authors: Olson Madeline T. , Wojtynek Nicholas E. , Talmon Geoffrey A. , Caffrey Thomas C. , Radhakrishnan Prakash , Ly Quan P. , Hollingsworth Michael A. , Mohs Aaron M.
Published: April 2023

Supplementary Figure S3 shows the internalization of AR9.6-IRDye800 in vitro.
Supplementary Figure S2 from Development of a MUC16-Targeted Near-Infrared Fluorescent Antibody Conjugate for Intraoperative Imaging of Pancreatic Cancer
Authors: Olson Madeline T. , Wojtynek Nicholas E. , Talmon Geoffrey A. , Caffrey Thomas C. , Radhakrishnan Prakash , Ly Quan P. , Hollingsworth Michael A. , Mohs Aaron M.
Published: April 2023

Supplementary Figure S2 shows the biodistribution of fluorescent conjugates in subcutaneous xenografts at 144 h post-injection.
Supplementary Figure S1 from Development of a MUC16-Targeted Near-Infrared Fluorescent Antibody Conjugate for Intraoperative Imaging of Pancreatic Cancer
Authors: Olson Madeline T. , Wojtynek Nicholas E. , Talmon Geoffrey A. , Caffrey Thomas C. , Radhakrishnan Prakash , Ly Quan P. , Hollingsworth Michael A. , Mohs Aaron M.
Published: April 2023

Supplementary Figure S1 shows the fluorescence imaging dynamics of AR9.6-IRDye800 in a Colo357 subcutaneous xenograft model.
Figure S2 from Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma
Authors: Martín-Broto Javier , Pousa Antonio López , Brohl Andrew S. , Van Tine Brian A. , Powers Benjamin , Stacchiotti Silvia , Blay Jean-Yves , Hu James S. , Oakley Gerard J. , Wang Hong , Szpurka Anna M. , Levy Donna E. , Mo Gary , Ceccarelli Matteo , Jones Robin L.
Published: April 2023

CONSORT diagram for patient disposition and availability of biomarker for analyses.
Supplementary Figure 2 from Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers
Authors: Hagerty Brendan , O'Sullivan T. Norene , Zhang Xianyu , Collins N. Keith , Custer Lawrence Wendi , Bassel Laura L. , Pate Nathan , Xu Jian , Guerin Theresa M. , Kozlov Serguei , Alewine Christine
Published: April 2023

Supplemental Figure 2. A) KPCdelMsln+hMSLN cells were treated with increasing concentrations of LMB-100 for 72 hours then viability was measured by colorimetric assay. B) IHC characterization of tumors that form following orthotopic implantation of KPCdelMsln and KPCdelMsln+hMSLN tumor cells into C57Bl/6 syngeneic mice. In each set of three images, the scale bars are: 7mm (whole tumor images for top two sets and bottom left sets) and 8mm (a whole tumor image for bottom right set); 600 ï�­m (intermediate magnification insets in all four sets); 100 ï�­m (high magnification insets in all four sets). C) KPCdelMsln+hMSLN cells were inoculated IP into Msl mice. Mice were euthanized at various time points and all tumor tissue was dissected from the peritoneal cavity and weighed to determine total tumor burden. Blood collected at time of euthanasia was assessed for serum hMSLN by ELISA. Correlation was assessed by Pearson method.
Supplementary table from A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers
Authors: Kawakami Masanori , Mustachio Lisa Maria , Chen Yulong , Chen Zibo , Liu Xiuxia , Wei Cheng-Hsin , Roszik Jason , Kittai Adam S. , Danilov Alexey V. , Zhang Xiaoshan , Fang Bingliang , Wang Jing , Heymach John V. , Tyutyunyk-Massey Liliya , Freemantle Sarah J. , Kurie Jonathan M. , Liu Xi , Dmitrovsky Ethan
Published: April 2023

Supplementary table
Supplementary Figure 1 from The Role of Specific ATP-Binding Cassette Transporters in the Acquired Resistance to Pyrrolobenzodiazepine Dimer–Containing Antibody–Drug Conjugates
Authors: Corbett Simon , Huang Shiran , Zammarchi Francesca , Howard Philip W. , van Berkel Patrick H. , Hartley John A.
Published: April 2023

Supplementary Figure 1. Cross-resistance of Karpas-299 and NCI-N87 resistant cell lines to common DNA interacting chemotherapeutic drugs. A. Continuous 72 h exposure in vitro growth inhibition of Karpas-299 wt, ADCr and PBDr cell lines to Cisplatin, Doxorubicin and Melphalan. B. Continuous 144 h exposure in vitro growth inhibition of NCI-N87 wt, ADCr and PBDr cell lines to Cisplatin, Doxorubicin and Melphalan. Each data point represents the average of at least 3 biological repeats with +/- SD error bars.
Table S2 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Authors: Busacca Sara , O'Regan Laura , Singh Anita , Sharkey Annabel J. , Dawson Alan G. , Dzialo Joanna , Parsons Aimee , Kumar Neelam , Schunselaar Laurel M. , Guppy Naomi , Nakas Apostolos , Sheaff Michael , Mansfield Aaron S. , Janes Sam M. , Baas Paul , Fry Andrew M. , Fennell Dean A.
Published: April 2023

Patient characteristics (explants cohort, n=20)
Supplementary Figures 1-3 and Tables 1-6 from MMAE Delivery Using the Bicycle Toxin Conjugate BT5528
Authors: Bennett Gavin , Brown Amy , Mudd Gemma , Huxley Philip , Van Rietschoten Katerine , Pavan Silvia , Chen Liuhong , Watcham Sophie , Lahdenranta Johanna , Keen Nicholas
Published: April 2023

Supplementary data are provided to further understand the pharmacokinetics and efficacy of BT5528 and EphA2 expression in tumors. Figure S1: Plasma concentration-time curves of BT5528 and MMAE following IV dosing of BT5528 1 in mouse, rat, and cynomolgus Monkey at 1 mg/kg (n=3 per species). Related to in vivo PK. Figure S2: EphA2 expression and tumour growth inhibition in CDX and PDX xenograft models are correlated. BT5528 3 mg/kg qw dosing has a range of anti-tumour activities across different cell-line derived and patient-derived xenograft models (*p<0.05, **p<0.01, ***p<0.001 2way ANOVA from D0 to last day of vehicle tumour measurement).Data used to generate Figure 3. Figure S3: EphA2 Immunohistochemistry staining of CDX and PDX xenograft models. A range of EphA2 expression is observed in stained tumour tissue from mouse xenograft models. Related to figure 3. Table T1: Ki values for BT5528, 1C1-mcMMAF and control compounds binding to human, mouse and rat Epha2 receptor. Ki values for Bicycle, BTC and DOTA analogues used to generate data in Figures 1, 4 and 5. Table T2: Binding affinities for BT5528 binding to EphA and EphB tyrosine kinases receptors determined by Surface Plasmon Resonance. Data defining BTC and Bicycle KD values for EphA2 orthologues. Table T3: In vitro ADME properties of BT5528 in mouse, rat, NHP and human: plasma protein binding, plasma stability and metabolic stability in hepatocytes. Related to in vitro ADME properties of BT5528. Table T4: Summary of experimentally determined and calculated PK Parameters for BT5528 and MMAE Following IV Dosing of 1 mg/kg BT5528 in Mouse, Rat and Cynomolgus Monkey. Related to in vivo PK Table T5a: Anti-Human EphA2 Antibody Binding Sites on CDX Cell Lines. Expression data used to generate Figure 3. Table T5b:Anti-Human EphA2 Antibody Binding Sites on PDX Cell Lines. Expression data used to generate Figure 3. Table T6: Doses of BT5528 and corresponding toxin (MMAE) used in preclinical toxicology studies compared with the clinical dose of MED-547 and corresponding toxin (MMAF)1. Related to the discussion (ADC versus BTC toxicology responses).
Supplementary Figure from Optimal Strategy and Benefit of Pulsed Therapy Depend On Tumor Heterogeneity and Aggressiveness at Time of Treatment Initiation
Authors: Mathur Deepti , Taylor Bradford P. , Chatila Walid K. , Scher Howard I. , Schultz Nikolaus , Razavi Pedram , Xavier Joao B.
Published: April 2023

Supplementary Figure from Optimal Strategy and Benefit of Pulsed Therapy Depend On Tumor Heterogeneity and Aggressiveness at Time of Treatment Initiation
Figure S4 from Hormone-Dependent Prostate Cancers are Dependent on Rac Signaling for Growth and Survival
Authors: Goka Erik T. , Mesa Lopez Dayrelis T. , Lippman Marc E.
Published: April 2023

Supplementary Figure 4. Rac inhibition in Prostate Cancer. (A) Migration Assay on DU145 cells treated with vehicle or GYS32661. (B) Pan-Kinase RPPA analysis of LnCaP cells treated with vehicle or GYS32661.
Figure S1 from Hormone-Dependent Prostate Cancers are Dependent on Rac Signaling for Growth and Survival
Authors: Goka Erik T. , Mesa Lopez Dayrelis T. , Lippman Marc E.
Published: April 2023

Supplementary Figure 1. A) Rac1 DNA copy number in blood, normal prostate, and prostate adenocarcinoma from patients in the TCGA PRAD dataset B) Rac1 mRNA expression of normal prostate and prostate adenocarcinoma from the TCGA PRAD dataset.
Supplementary Data from Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer
Authors: Furman Craig , Puyang Xiaoling , Zhang Zhaojie , Wu Zhenhua J. , Banka Deepti , Aithal Kiran B. , Albacker Lee A. , Hao Ming-Hong , Irwin Sean , Kim Amy , Montesion Meagan , Moriarty Alyssa D. , Murugesan Karthikeyan , Nguyen Tuong-Vi , Rimkunas Victoria , Sahmoud Tarek , Wick Michael J. , Yao Shihua , Zhang Xun , Zeng Hao , Vaillancourt Frédéric H. , Bolduc David M. , Larsen Nicholas , Zheng Guo Zhu , Prajapati Sudeep , Zhu Ping , Korpal Manav
Published: April 2023

Supplementary Data from Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer
Figure S3 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
Authors: Perera Samanthi A. , Kopinja Johnny E. , Ma Yanhong , Muise Eric S. , Laskey Jason , Chakravarthy Kalyan , Chen Yiping , Cui Long , Presland Jeremy , Sathe Manjiri , Javaid Sarah , Minnihan Ellen C. , Ferguson Heidi M. , Piesvaux Jennifer , Pan Bo-Sheng , Zhao Shuxia , Sharma Sharad K. , Woo Hyun Chong , Pucci Vincenzo , Knemeyer Ian , Cemerski Saso , Cumming Jared , Trotter B. Wesley , Tse Archie , Khilnani Anuradha , Ranganath Sheila , Long Brian J. , Bennett David Jonathan , Addona George H.
Published: April 2023

Supplemental Figure 3: MC38 tumor growth in C57BL/6, Nude or NSG mice and comparison of systemic cytokines
Figure S2 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
Authors: Perera Samanthi A. , Kopinja Johnny E. , Ma Yanhong , Muise Eric S. , Laskey Jason , Chakravarthy Kalyan , Chen Yiping , Cui Long , Presland Jeremy , Sathe Manjiri , Javaid Sarah , Minnihan Ellen C. , Ferguson Heidi M. , Piesvaux Jennifer , Pan Bo-Sheng , Zhao Shuxia , Sharma Sharad K. , Woo Hyun Chong , Pucci Vincenzo , Knemeyer Ian , Cemerski Saso , Cumming Jared , Trotter B. Wesley , Tse Archie , Khilnani Anuradha , Ranganath Sheila , Long Brian J. , Bennett David Jonathan , Addona George H.
Published: April 2023

Supplemental Figure 2: STING agonists stimulate cytokines in tumor, plasma and peripheral tissues following IT dosing.
Supplementary Table 2 from Phosphoproteomics Identifies PI3K Inhibitor–selective Adaptive Responses in Pancreatic Cancer Cell Therapy and Resistance
Authors: Cintas Célia , Douche Thibault , Dantes Zahra , Mouton-Barbosa Emmanuelle , Bousquet Marie-Pierre , Cayron Coralie , Therville Nicole , Pont Frédéric , Ramos-Delgado Fernanda , Guyon Camille , Garmy-Susini Barbara , Cappello Paola , Burlet-Schiltz Odile , Hirsch Emilio , Gomez-Brouchet Anne , Thibault Benoît , Reichert Maximilian , Guillermet-Guibert Julie
Published: April 2023

Supplementary Table 2 contains the list of isoform selective peptides in each condition, with quantification and global pathway analysis.
Supplementary Methods from Phosphoproteomics Identifies PI3K Inhibitor–selective Adaptive Responses in Pancreatic Cancer Cell Therapy and Resistance
Authors: Cintas Célia , Douche Thibault , Dantes Zahra , Mouton-Barbosa Emmanuelle , Bousquet Marie-Pierre , Cayron Coralie , Therville Nicole , Pont Frédéric , Ramos-Delgado Fernanda , Guyon Camille , Garmy-Susini Barbara , Cappello Paola , Burlet-Schiltz Odile , Hirsch Emilio , Gomez-Brouchet Anne , Thibault Benoît , Reichert Maximilian , Guillermet-Guibert Julie
Published: April 2023

This file contains the additional information for Material and method, including method for cell transduction, cell treatment and WB, RT-qPCR analysis, viablity assays, proliferation assays, DEVD cleavage assay, flow cytometry, soft agar assay, organoid and soft agar assay quantification and ImageJ plugin, scriot for analaysis of unpaired heavy/light phosphopeptides, method for SILAC labelling, SILAC sample preparation, data-dependent acquisition LC-MS/MS, phosphoproteomic data analysis, mice housing, details on statistics, as well as Legends of supplementary figures and tables, table with sequences of shRNAs, used antibodies, RT-qPCR primers.
Supplementary Figures from Phosphoproteomics Identifies PI3K Inhibitor–selective Adaptive Responses in Pancreatic Cancer Cell Therapy and Resistance
Authors: Cintas Célia , Douche Thibault , Dantes Zahra , Mouton-Barbosa Emmanuelle , Bousquet Marie-Pierre , Cayron Coralie , Therville Nicole , Pont Frédéric , Ramos-Delgado Fernanda , Guyon Camille , Garmy-Susini Barbara , Cappello Paola , Burlet-Schiltz Odile , Hirsch Emilio , Gomez-Brouchet Anne , Thibault Benoît , Reichert Maximilian , Guillermet-Guibert Julie
Published: April 2023

Supplementary Figures file contains merged Figure S1 to S8 including description of cell lines, Human samples, PI3K inhibitor stability, SILAC setup and controls, STRING analysis, quantifications of WB and cellular assays, prediction of kinase motifs found regulated, effects of combination of treatment in vitro, correlation between cell survival and phosphopeptide intensity, effects of combination treatment in Human samples and in vivo.
Figure S1 from Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK
Authors: Lau David K. , Luk Ian Y. , Jenkins Laura J. , Martin Andrew , Williams David S. , Schoffer Kael L. , Chionh Fiona , Buchert Michael , Sjoquist Katrin , Boussioutas Alex , Hayes Sarah A. , Ernst Matthias , Weickhardt Andrew J. , Pavlakis Nick , Tebbutt Niall C. , Mariadason John M.
Published: April 2023

Supplementary Figure 1
Supplementary Data from ASN004, A 5T4-targeting scFv-Fc Antibody–Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models
Authors: Smith Roger A. , Zammit David J. , Damle Nitin K. , Usansky Helen , Reddy Sanjeeva P. , Lin Jun-Hsiang , Mistry Mahesh , Rao Niranjan S. , Denis Louis J. , Gupta Sandeep
Published: April 2023

Supplementary Data and Figures S1 to S6
Video 2 from Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGAS–STING Signaling in Triple-Negative Breast Cancer
Authors: Hu Yang , Manasrah Baraa K. , McGregor Stephanie M. , Lera Robert F. , Norman Roshan X. , Tucker John B. , Scribano Christina M. , Yan Rachel E. , Humayun Mouhita , Wisinski Kari B. , Tevaarwerk Amye J. , O'Regan Ruth M. , Wilke Lee G. , Weaver Beth A. , Beebe David J. , Jin Ning , Burkard Mark E.
Published: April 2023

Multinucleated H2B-RFP Tub-GFP MDA-MB-231 Multipolar Division
Supplementary Data (for Review only) from The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b
Authors: Bodyak Natalya D. , Mosher Rebecca , Yurkovetskiy Aleksandr V. , Yin Mao , Bu Charlie , Conlon Patrick R. , Demady Damon R. , DeVit Michael J. , Gumerov Dmitry R. , Gurijala Venu R. , Lee Winnie , McGillicuddy Dennis , Park Peter U. , Poling Laura L. , Protopova Marina , Qin LiuLiang , Stevenson Cheri A. , Ter-Ovanesyan Elena , Uttard Alex , Xiao Dongmei , Xu Jian , Xu Ling , Bergstrom Donald A. , Lowinger Timothy B.
Published: April 2023

This is a second manuscript describing the Dolaflexin platform employed in XMT-1536. We have submitted this manuscript for consideration for co-publication with this XMT-1536 manuscript, and provide it here to hopefully facilitate the reviewers assessment.
Dolaflexin Manuscript Figures 2-6 from The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b
Authors: Bodyak Natalya D. , Mosher Rebecca , Yurkovetskiy Aleksandr V. , Yin Mao , Bu Charlie , Conlon Patrick R. , Demady Damon R. , DeVit Michael J. , Gumerov Dmitry R. , Gurijala Venu R. , Lee Winnie , McGillicuddy Dennis , Park Peter U. , Poling Laura L. , Protopova Marina , Qin LiuLiang , Stevenson Cheri A. , Ter-Ovanesyan Elena , Uttard Alex , Xiao Dongmei , Xu Jian , Xu Ling , Bergstrom Donald A. , Lowinger Timothy B.
Published: April 2023

These are figures associated with a second manuscript that has been submitted for consideration for co-publication. It describes the platform and hopefully will facilitate the reviewers' assessment of this manuscript on XMT-1536. we are happy to make this available as supplementary data for publication in any format if desired.
Supplementary Data from Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGAS–STING Signaling in Triple-Negative Breast Cancer
Authors: Hu Yang , Manasrah Baraa K. , McGregor Stephanie M. , Lera Robert F. , Norman Roshan X. , Tucker John B. , Scribano Christina M. , Yan Rachel E. , Humayun Mouhita , Wisinski Kari B. , Tevaarwerk Amye J. , O'Regan Ruth M. , Wilke Lee G. , Weaver Beth A. , Beebe David J. , Jin Ning , Burkard Mark E.
Published: April 2023

Supplementary Data
Supplementary Figure from Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma
Authors: Shi Yijiang , Sun Fumou , Cheng Yan , Holmes Brent , Dhakal Binod , Gera Joseph F. , Janz Siegfried , Lichtenstein Alan
Published: April 2023

Supplementary Figure from Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma
Supplementary Data from The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms
Authors: Ferng Timothy T. , Terada Daisuke , Ando Makoto , Tarver Theodore C. , Chaudhary Fihr , Lin Kimberly C. , Logan Aaron C. , Smith Catherine C.
Published: April 2023

Supplementary Data from The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms
Supplementary Figure from Porcupine Inhibition Disrupts Mitochondrial Function and Homeostasis in WNT Ligand–Addicted Pancreatic Cancer
Authors: Aguilera Kristina Y. , Le Thuc , Riahi Rana , Lay Anna R. , Hinz Stefan , Saadat Edris A. , Vashisht Ajay A. , Wohlschlegel James , Donahue Timothy R. , Radu Caius G. , Dawson David W.
Published: April 2023

Supplementary Figure from Porcupine Inhibition Disrupts Mitochondrial Function and Homeostasis in WNT Ligand–Addicted Pancreatic Cancer
Supplementary Table from Targeting Protein Arginine Methyltransferase 5 Suppresses Radiation-induced Neuroendocrine Differentiation and Sensitizes Prostate Cancer Cells to Radiation
Authors: Owens Jake L. , Beketova Elena , Liu Sheng , Shen Qi , Pawar Jogendra Singh , Asberry Andrew M. , Yang Jie , Deng Xuehong , Elzey Bennett D. , Ratliff Timothy L. , Cheng Liang , Choo Richard , Citrin Deborah E. , Polascik Thomas J. , Wang Bangchen , Huang Jiaoti , Li Chenglong , Wan Jun , Hu Chang-Deng
Published: April 2023

Supplementary Table from Targeting Protein Arginine Methyltransferase 5 Suppresses Radiation-induced Neuroendocrine Differentiation and Sensitizes Prostate Cancer Cells to Radiation
Supplementary Table 1 from ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer
Authors: Ferrarini Isacco , Louie Anna , Zhou Lanlan , El-Deiry Wafik S.
Published: April 2023

Supplementary Table S1: list of antibodies used in this study for western blots (WB), immunofluorescence (IF) and immunohistochemistry (IHC.)
Supplementary Figures from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance
Authors: Jensen-Pergakes Kristen , Tatlock John , Maegley Karen A. , McAlpine Indrawan J. , McTigue Michele , Xie Tao , Dillon Christopher P. , Wang Yuli , Yamazaki Shinji , Spiegel Noah , Shi Manli , Nemeth Amy , Miller Natalie , Hendrickson Eleanore , Lam Hieu , Sherrill John , Chung Chi-Yeh , McMillan Elizabeth A. , Bryant Shannon Karlicek , Palde Prakash , Braganza John , Brooun Alexei , Deng Ya-Li , Goshtasbi Vesta , Kephart Susan E. , Kumpf Robert A. , Liu Wei , Patman Ryan L. , Rui Eugene , Scales Stephanie , Tran-Dube Michelle , Wang Fen , Wythes Martin , Paul Thomas A.
Published: April 2023

Supplemental Figures S1-S8
Supplementary Movie 5 from Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors
Authors: Keddy Clare , Shinde Pushkar , Jones Kristen , Kaech Stefanie , Somwar Romel , Shinde Ujwal , Davare Monika A.
Published: April 2023

Supplementary Movie 5
Z-stack Animation of live confocal imaging.
Supplementary Data S2 from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance
Authors: Jensen-Pergakes Kristen , Tatlock John , Maegley Karen A. , McAlpine Indrawan J. , McTigue Michele , Xie Tao , Dillon Christopher P. , Wang Yuli , Yamazaki Shinji , Spiegel Noah , Shi Manli , Nemeth Amy , Miller Natalie , Hendrickson Eleanore , Lam Hieu , Sherrill John , Chung Chi-Yeh , McMillan Elizabeth A. , Bryant Shannon Karlicek , Palde Prakash , Braganza John , Brooun Alexei , Deng Ya-Li , Goshtasbi Vesta , Kephart Susan E. , Kumpf Robert A. , Liu Wei , Patman Ryan L. , Rui Eugene , Scales Stephanie , Tran-Dube Michelle , Wang Fen , Wythes Martin , Paul Thomas A.
Published: April 2023

AUC and EC50 values for PF-06939999 treated NSCLC cells
Supplementary Movie 3 from Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors
Authors: Keddy Clare , Shinde Pushkar , Jones Kristen , Kaech Stefanie , Somwar Romel , Shinde Ujwal , Davare Monika A.
Published: April 2023

Supplementary Movie 3
Z-stack Animation of live confocal imaging.
Supplementary Data S1 from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance
Authors: Jensen-Pergakes Kristen , Tatlock John , Maegley Karen A. , McAlpine Indrawan J. , McTigue Michele , Xie Tao , Dillon Christopher P. , Wang Yuli , Yamazaki Shinji , Spiegel Noah , Shi Manli , Nemeth Amy , Miller Natalie , Hendrickson Eleanore , Lam Hieu , Sherrill John , Chung Chi-Yeh , McMillan Elizabeth A. , Bryant Shannon Karlicek , Palde Prakash , Braganza John , Brooun Alexei , Deng Ya-Li , Goshtasbi Vesta , Kephart Susan E. , Kumpf Robert A. , Liu Wei , Patman Ryan L. , Rui Eugene , Scales Stephanie , Tran-Dube Michelle , Wang Fen , Wythes Martin , Paul Thomas A.
Published: April 2023

Whole exome sequencing results from PRMT5 inhibitor resistant cells
Supplementary figure FS4 from Neoadjuvant Radiation Therapy and Surgery Improves Metastasis-Free Survival over Surgery Alone in a Primary Mouse Model of Soft Tissue Sarcoma
Authors: Patel Rutulkumar , Mowery Yvonne M. , Qi Yi , Bassil Alex M. , Holbrook Matt , Xu Eric S. , Hong Cierra S. , Himes Jonathon E. , Williams Nerissa T. , Everitt Jeffrey , Ma Yan , Luo Lixia , Selitsky Sara R. , Modliszewski Jennifer L. , Gao Junheng , Jung Sin-Ho , Kirsch David G. , Badea Cristian T.
Published: April 2023

Long-term metastases study of an autochthonous p53/MCA mouse model of STS induced by Cre-LoxP technology using TRP53 fl/fl mice
Supplementary Data from Transient Inhibition of Trastuzumab–Tumor Binding to Overcome the “Binding-Site Barrier” and Improve the Efficacy of a Trastuzumab–Gelonin Immunotoxin
Authors: Chen Ping , Bordeau Brandon M. , Zhang Yu , Balthasar Joseph P.
Published: April 2023

Supplementary Data from Transient Inhibition of Trastuzumab–Tumor Binding to Overcome the “Binding-Site Barrier” and Improve the Efficacy of a Trastuzumab–Gelonin Immunotoxin
Supplementary Data from Antibody–Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release
Authors: Kopp Anna , Hofsess Scott , Cardillo Thomas M. , Govindan Serengulam V. , Donnell Jennifer , Thurber Greg M.
Published: April 2023

Supplemental Figures S1-S8, supplemental methods
Supplementary Data from Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma
Authors: Pribnow Allison , Jonchere Barbara , Liu Jingjing , Smith Kyle S. , Campagne Olivia , Xu Ke , Robinson Sarah , Patel Yogesh , Onar-Thomas Arzu , Wu Gang , Stewart Clinton F. , Northcott Paul A. , Yu Jiyang , Robinson Giles W. , Roussel Martine F.
Published: April 2023

Supplementary Data from Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma
Supplementary Materials SM1 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
Authors: Peng Peng , Qiang Xiaoyan , Li Guoyu , Li Lin , Ni Shumao , Yu Qi , Sourd Laura , Marangoni Elisabetta , Hu Chao , Wang Dong , Wu Di , Wu Frank
Published: April 2023

This includes the supplementary methods and supplementary table captions.
Figure FS7 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
Authors: Peng Peng , Qiang Xiaoyan , Li Guoyu , Li Lin , Ni Shumao , Yu Qi , Sourd Laura , Marangoni Elisabetta , Hu Chao , Wang Dong , Wu Di , Wu Frank
Published: April 2023

Tinengotinib blunts EMT in TNBC.
Figure FS5 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
Authors: Peng Peng , Qiang Xiaoyan , Li Guoyu , Li Lin , Ni Shumao , Yu Qi , Sourd Laura , Marangoni Elisabetta , Hu Chao , Wang Dong , Wu Di , Wu Frank
Published: April 2023

72h-treament of tinengotinib strongly inhibits HUVEC cell viability in a dose-dependent manner.
Supplementary Figure from Sustained Supratherapeutic Paclitaxel Delivery Enhances Irreversible Sarcoma Cell Death
Authors: Blessing William A. , Digesu Christopher S. , Liu Rong , Mahvi David A. , Tal-mason Aya , Kumar Anil , Hachey Krista J. , Colby Aaron H. , Korunes-Miller Jenny T. , Agar Natalie , Regan Michael S. , Shih Angela , Raut Chandrajit P. , Grinstaff Mark W. , Colson Yolonda L.
Published: April 2023

Supplementary Figure from Sustained Supratherapeutic Paclitaxel Delivery Enhances Irreversible Sarcoma Cell Death
Supplementary Data S1 from Inhibition of Wnt Signaling in Colon Cancer Cells via an Oral Drug that Facilitates TNIK Degradation
Authors: Zhou Kun , Cheong Jae Eun , Krishnaji Subrahmanian Tarakkad , Ghalali Aram , Fu Haojie , Sui Lufei , Alix-Panabières Catherine , Cayrefourcq Laure , Bielenberg Diane , Sun Lijun , Zetter Bruce
Published: April 2023

Supplementary figures and table
Supplementary Data from N6-Methyladenosine RNA Modifications Regulate the Response to Platinum Through Nicotinamide N-methyltransferase
Authors: Huang Hao , Zhao Guangyuan , Cardenas Horacio , Valdivia Andres Felipe , Wang Yinu , Matei Daniela
Published: April 2023

Supplementary Figures and Tables
Supplementary Figure S7 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
Authors: Evans Rachel J. , Perkins Douglas W. , Selfe Joanna , Kelsey Anna , Birch Gavin P. , Shipley Janet M. , Schipper Koen , Isacke Clare M.
Published: April 2023

Immunohistochemical staining and quantification of the effect of A5/158, A5/158-vc-MMAE and Isotype-vc-MMAE treatment on the spontaneous metastasis of MG-63 cells to the liver in NSG mice.
Supplementary Figure S6 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
Authors: Evans Rachel J. , Perkins Douglas W. , Selfe Joanna , Kelsey Anna , Birch Gavin P. , Shipley Janet M. , Schipper Koen , Isacke Clare M.
Published: April 2023

Continuation of Figure S5 showing the effect of A5/158-vc-MMAE treatment on the spontaneous metastatic spread of MG-63 cells to the lungs and liver.
Supplementary Figure S1 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
Authors: Evans Rachel J. , Perkins Douglas W. , Selfe Joanna , Kelsey Anna , Birch Gavin P. , Shipley Janet M. , Schipper Koen , Isacke Clare M.
Published: April 2023

Examples of Endo180 positive and negative staining in subtypes of soft tissue sarcoma tumor cores.
Supplementary Table S4 from ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs
Authors: Tsukamoto Shuntaro , Sugi Naoko Hata , Nishibata Kyoko , Nakazawa Youya , Ito Daisuke , Fukushima Sayo , Nakagawa Takayuki , Ichikawa Kenji , Kato Yu , Kakiuchi Dai , Goto Aya , Itoh-Yagi Machiko , Aota Tomoki , Inoue Satoshi , Yamane Yoshinobu , Murai Norio , Azuma Hiroshi , Nagao Satoshi , Sasai Ken , Akagi Tsuyoshi , Imai Toshio , Matsui Junji , Matsushima Tomohiro
Published: April 2023

Supplementary Table S4
Suppl Figure 3 from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER
Authors: Hsu Jeff , Chong Colin , Serrill Jeffrey , Goon Levina , Balayan Joan , Johnson Eric N. , Lorenzana Grachelle , Wu Sharon , Leong Kevin G. , Yun Theodore J. , Wang Yong , Jiang Faming , Bannen Lynne , Lamb Peter , Xu Wei , Yu Peiwen
Published: April 2023

Suppl Figure 3
Supplementary Data from Comparative Oncology Assessment of a Novel Inhibitor of Valosin-Containing Protein in Tumor-Bearing Dogs
Authors: LeBlanc Amy K. , Mazcko Christina N. , Fan Timothy M. , Vail David M. , Flesner Brian K. , Bryan Jeffrey N. , Li Shan , Wang Feng , Harris Scott , Vargas Jesse D. , Govindharajulu Jeevan P. , Jaganathan Soumya , Tomaino Francesca , Srivastava Apurva K. , Chou Tsui-Fen , Stott Gordon M. , Covey Joseph M. , Mroczkowski Barbara , Doroshow James H.
Published: April 2023

Supplementary Data from Comparative Oncology Assessment of a Novel Inhibitor of Valosin-Containing Protein in Tumor-Bearing Dogs
Supplementary Data from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
Authors: Llaurado Fernandez Marta , Hijmans E. Marielle , Gennissen Annemiek M.C. , Wong Nelson K.Y. , Li Shang , Wisman G. Bea A. , Hamilton Aleksandra , Hoenisch Joshua , Dawson Amy , Lee Cheng-Han , Bittner Madison , Kim Hannah , DiMattia Gabriel E. , Lok Christianne A.R. , Lieftink Cor , Beijersbergen Roderick L. , de Jong Steven , Carey Mark S. , Bernards René , Berns Katrien
Published: April 2023

Supplementary Data from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
Supplementary Data from Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody–drug Conjugate Targeting ADAM9-expressing Tumors
Authors: Scribner Juniper A. , Hicks Stuart W. , Sinkevicius Kerstin W. , Yoder Nicholas C. , Diedrich Gundo , Brown Jennifer G. , Lucas Jacquelynn , Fuller Megan E. , Son Thomas , Dastur Anahita , Hooley Jeff , Espelin Christopher , Themeles Marian , Chen Francine Z. , Li Ying , Chiechi Michael , Lee Jenny , Barat Bhaswati , Widjaja Lusiana , Gorlatov Sergey , Tamura James , Ciccarone Valentina , Ab Olga , McEachem Kerry A. , Koenig Scott , Westin Eric H. , Moore Paul A. , Chittenden Thomas , Gregory Richard J. , Bonvini Ezio , Loo Deryk
Published: April 2023

Supplementary Data from Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody–drug Conjugate Targeting ADAM9-expressing Tumors